Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + bendamustine in pretreated HER2-negative advanced or metastatic breast cancer
2012-005593-64Phase 2Completed
- Sponsor
- AGMT
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and bendamustine in breast cancer, sponsored by AGMT. Primary endpoint: Overall response rate. Started May 2013; status: completed.
02
Drugs
capecitabinebendamustine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-005593-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005593-64.